Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Phathom Pharmaceuticals, Inc. (PHAT)

Compare
5.49
+0.37
+(7.23%)
At close: April 2 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
55,252
55,252
682
--
--
Cost of Revenue
7,973
7,973
167
--
--
Gross Profit
47,279
47,279
515
--
--
Operating Expense
324,746
324,746
167,827
172,440
135,080
Operating Income
-277,467
-277,467
-167,312
-172,440
-135,080
Net Non Operating Interest Income Expense
-56,851
-56,851
-34,092
-25,173
-6,747
Other Income Expense
-8
-8
-188
-110
-2,056
Pretax Income
-334,326
-334,326
-201,592
-197,723
-143,883
Net Income Common Stockholders
-334,326
-334,326
-201,592
-197,723
-143,883
Diluted NI Available to Com Stockholders
-334,326
-334,326
-201,592
-197,723
-143,883
Basic EPS
-5.29
--
-3.93
-5.05
-3.89
Diluted EPS
-5.29
--
-3.93
-5.05
-3.89
Basic Average Shares
63,176.21
--
51,289.09
39,118.22
37,002.96
Diluted Average Shares
63,176.21
--
51,289.09
39,118.22
37,002.96
Total Operating Income as Reported
-277,467
-277,467
-167,312
-172,440
-135,080
Total Expenses
332,719
332,719
167,994
172,440
135,080
Net Income from Continuing & Discontinued Operation
-334,326
-334,326
-201,592
-197,723
-143,883
Normalized Income
-334,326
-334,326
-201,592
-197,723
-143,883
Interest Income
15,158
15,158
7,876
2,132
41
Interest Expense
72,009
72,009
41,968
27,305
6,788
Net Interest Income
-56,851
-56,851
-34,092
-25,173
-6,747
EBIT
-262,317
-262,317
-159,624
-170,418
-137,095
EBITDA
-261,522
-261,522
-159,049
-169,798
-136,574
Reconciled Cost of Revenue
7,973
7,973
167
--
--
Reconciled Depreciation
795
795
575
620
521
Net Income from Continuing Operation Net Minority Interest
-334,326
-334,326
-201,592
-197,723
-143,883
Normalized EBITDA
-261,522
-261,522
-159,049
-169,798
-136,574
12/31/2021 - 10/25/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALMS Alumis Inc.
9.84
+35.91%
 
EWTX Edgewise Therapeutics, Inc.
15.52
-22.90%
 
DAWN Day One Biopharmaceuticals, Inc.
7.97
+4.73%
 
STOK Stoke Therapeutics, Inc.
6.60
+5.94%
 
SWTX SpringWorks Therapeutics, Inc.
46.52
+11.08%
 
IDYA IDEAYA Biosciences, Inc.
16.35
+10.70%
 
KYMR Kymera Therapeutics, Inc.
26.36
+4.46%
 
SNDX Syndax Pharmaceuticals, Inc.
12.97
+7.99%
 
VRNA Verona Pharma plc
60.29
+2.99%
 
BCYC Bicycle Therapeutics plc
8.05
+2.55%